Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 14 |
NetGPI | no | yes: 0, no: 14 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005634 | nucleus | 5 | 2 |
GO:0005737 | cytoplasm | 2 | 2 |
GO:0043226 | organelle | 2 | 2 |
GO:0043227 | membrane-bounded organelle | 3 | 2 |
GO:0043229 | intracellular organelle | 3 | 2 |
GO:0043231 | intracellular membrane-bounded organelle | 4 | 2 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
Related structures:
AlphaFold database: E9AD71
Term | Name | Level | Count |
---|---|---|---|
GO:0000956 | nuclear-transcribed mRNA catabolic process | 7 | 2 |
GO:0006139 | nucleobase-containing compound metabolic process | 3 | 2 |
GO:0006401 | RNA catabolic process | 5 | 2 |
GO:0006402 | mRNA catabolic process | 6 | 2 |
GO:0006725 | cellular aromatic compound metabolic process | 3 | 2 |
GO:0006807 | nitrogen compound metabolic process | 2 | 2 |
GO:0008152 | metabolic process | 1 | 2 |
GO:0009056 | catabolic process | 2 | 2 |
GO:0009057 | macromolecule catabolic process | 4 | 2 |
GO:0009892 | negative regulation of metabolic process | 4 | 2 |
GO:0009987 | cellular process | 1 | 2 |
GO:0010468 | regulation of gene expression | 5 | 2 |
GO:0010605 | negative regulation of macromolecule metabolic process | 5 | 2 |
GO:0010629 | negative regulation of gene expression | 6 | 2 |
GO:0016070 | RNA metabolic process | 5 | 2 |
GO:0016071 | mRNA metabolic process | 6 | 2 |
GO:0019222 | regulation of metabolic process | 3 | 2 |
GO:0019439 | aromatic compound catabolic process | 4 | 2 |
GO:0034641 | cellular nitrogen compound metabolic process | 3 | 2 |
GO:0034655 | nucleobase-containing compound catabolic process | 4 | 2 |
GO:0043170 | macromolecule metabolic process | 3 | 2 |
GO:0044237 | cellular metabolic process | 2 | 2 |
GO:0044238 | primary metabolic process | 2 | 2 |
GO:0044248 | cellular catabolic process | 3 | 2 |
GO:0044260 | obsolete cellular macromolecule metabolic process | 3 | 2 |
GO:0044265 | obsolete cellular macromolecule catabolic process | 4 | 2 |
GO:0044270 | cellular nitrogen compound catabolic process | 4 | 2 |
GO:0046483 | heterocycle metabolic process | 3 | 2 |
GO:0046700 | heterocycle catabolic process | 4 | 2 |
GO:0048519 | negative regulation of biological process | 3 | 2 |
GO:0050789 | regulation of biological process | 2 | 2 |
GO:0060255 | regulation of macromolecule metabolic process | 4 | 2 |
GO:0065007 | biological regulation | 1 | 2 |
GO:0071704 | organic substance metabolic process | 2 | 2 |
GO:0090304 | nucleic acid metabolic process | 4 | 2 |
GO:1901360 | organic cyclic compound metabolic process | 3 | 2 |
GO:1901361 | organic cyclic compound catabolic process | 4 | 2 |
GO:1901575 | organic substance catabolic process | 3 | 2 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003676 | nucleic acid binding | 3 | 15 |
GO:0003723 | RNA binding | 4 | 2 |
GO:0003824 | catalytic activity | 1 | 15 |
GO:0004518 | nuclease activity | 4 | 15 |
GO:0004527 | exonuclease activity | 5 | 15 |
GO:0004532 | RNA exonuclease activity | 5 | 2 |
GO:0004534 | 5'-3' RNA exonuclease activity | 7 | 2 |
GO:0004540 | RNA nuclease activity | 4 | 2 |
GO:0005488 | binding | 1 | 15 |
GO:0008409 | 5'-3' exonuclease activity | 6 | 2 |
GO:0016787 | hydrolase activity | 2 | 15 |
GO:0016788 | hydrolase activity, acting on ester bonds | 3 | 15 |
GO:0016796 | exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 6 | 2 |
GO:0016896 | RNA exonuclease activity, producing 5'-phosphomonoesters | 6 | 2 |
GO:0097159 | organic cyclic compound binding | 2 | 15 |
GO:0140098 | catalytic activity, acting on RNA | 3 | 2 |
GO:0140640 | catalytic activity, acting on a nucleic acid | 2 | 2 |
GO:1901363 | heterocyclic compound binding | 2 | 15 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 202 | 206 | PF00656 | 0.571 |
CLV_C14_Caspase3-7 | 570 | 574 | PF00656 | 0.744 |
CLV_MEL_PAP_1 | 465 | 471 | PF00089 | 0.517 |
CLV_NRD_NRD_1 | 166 | 168 | PF00675 | 0.332 |
CLV_NRD_NRD_1 | 196 | 198 | PF00675 | 0.361 |
CLV_NRD_NRD_1 | 301 | 303 | PF00675 | 0.387 |
CLV_NRD_NRD_1 | 314 | 316 | PF00675 | 0.380 |
CLV_NRD_NRD_1 | 351 | 353 | PF00675 | 0.599 |
CLV_NRD_NRD_1 | 420 | 422 | PF00675 | 0.537 |
CLV_NRD_NRD_1 | 518 | 520 | PF00675 | 0.594 |
CLV_NRD_NRD_1 | 544 | 546 | PF00675 | 0.700 |
CLV_NRD_NRD_1 | 98 | 100 | PF00675 | 0.258 |
CLV_PCSK_FUR_1 | 349 | 353 | PF00082 | 0.628 |
CLV_PCSK_KEX2_1 | 196 | 198 | PF00082 | 0.361 |
CLV_PCSK_KEX2_1 | 301 | 303 | PF00082 | 0.359 |
CLV_PCSK_KEX2_1 | 314 | 316 | PF00082 | 0.418 |
CLV_PCSK_KEX2_1 | 351 | 353 | PF00082 | 0.615 |
CLV_PCSK_KEX2_1 | 518 | 520 | PF00082 | 0.598 |
CLV_PCSK_KEX2_1 | 556 | 558 | PF00082 | 0.783 |
CLV_PCSK_KEX2_1 | 98 | 100 | PF00082 | 0.256 |
CLV_PCSK_PC1ET2_1 | 351 | 353 | PF00082 | 0.595 |
CLV_PCSK_PC1ET2_1 | 556 | 558 | PF00082 | 0.723 |
CLV_PCSK_SKI1_1 | 108 | 112 | PF00082 | 0.322 |
CLV_PCSK_SKI1_1 | 314 | 318 | PF00082 | 0.497 |
CLV_PCSK_SKI1_1 | 331 | 335 | PF00082 | 0.266 |
CLV_PCSK_SKI1_1 | 34 | 38 | PF00082 | 0.361 |
CLV_PCSK_SKI1_1 | 353 | 357 | PF00082 | 0.538 |
DEG_APCC_DBOX_1 | 33 | 41 | PF00400 | 0.571 |
DEG_APCC_DBOX_1 | 75 | 83 | PF00400 | 0.555 |
DOC_CYCLIN_yCln2_LP_2 | 238 | 244 | PF00134 | 0.484 |
DOC_MAPK_gen_1 | 301 | 308 | PF00069 | 0.398 |
DOC_MAPK_gen_1 | 349 | 359 | PF00069 | 0.590 |
DOC_MAPK_gen_1 | 72 | 81 | PF00069 | 0.522 |
DOC_MAPK_gen_1 | 96 | 104 | PF00069 | 0.500 |
DOC_MAPK_MEF2A_6 | 274 | 282 | PF00069 | 0.335 |
DOC_MAPK_MEF2A_6 | 321 | 329 | PF00069 | 0.509 |
DOC_PP1_RVXF_1 | 272 | 278 | PF00149 | 0.332 |
DOC_PP2B_LxvP_1 | 345 | 348 | PF13499 | 0.574 |
DOC_USP7_MATH_1 | 204 | 208 | PF00917 | 0.579 |
DOC_USP7_MATH_1 | 47 | 51 | PF00917 | 0.532 |
DOC_USP7_MATH_1 | 558 | 562 | PF00917 | 0.767 |
DOC_WW_Pin1_4 | 124 | 129 | PF00397 | 0.567 |
LIG_14-3-3_CanoR_1 | 108 | 114 | PF00244 | 0.498 |
LIG_14-3-3_CanoR_1 | 352 | 359 | PF00244 | 0.586 |
LIG_14-3-3_CanoR_1 | 487 | 497 | PF00244 | 0.551 |
LIG_14-3-3_CanoR_1 | 52 | 59 | PF00244 | 0.555 |
LIG_14-3-3_CanoR_1 | 557 | 567 | PF00244 | 0.723 |
LIG_14-3-3_CanoR_1 | 98 | 103 | PF00244 | 0.498 |
LIG_AP2alpha_2 | 240 | 242 | PF02296 | 0.512 |
LIG_APCC_ABBA_1 | 139 | 144 | PF00400 | 0.541 |
LIG_APCC_ABBA_1 | 397 | 402 | PF00400 | 0.589 |
LIG_BRCT_BRCA1_1 | 385 | 389 | PF00533 | 0.492 |
LIG_eIF4E_1 | 171 | 177 | PF01652 | 0.571 |
LIG_eIF4E_1 | 233 | 239 | PF01652 | 0.482 |
LIG_eIF4E_1 | 312 | 318 | PF01652 | 0.458 |
LIG_FHA_1 | 159 | 165 | PF00498 | 0.558 |
LIG_FHA_1 | 340 | 346 | PF00498 | 0.578 |
LIG_FHA_1 | 352 | 358 | PF00498 | 0.427 |
LIG_FHA_1 | 372 | 378 | PF00498 | 0.464 |
LIG_FHA_1 | 437 | 443 | PF00498 | 0.701 |
LIG_FHA_1 | 444 | 450 | PF00498 | 0.617 |
LIG_FHA_1 | 496 | 502 | PF00498 | 0.480 |
LIG_FHA_1 | 508 | 514 | PF00498 | 0.458 |
LIG_FHA_1 | 76 | 82 | PF00498 | 0.472 |
LIG_FHA_2 | 200 | 206 | PF00498 | 0.533 |
LIG_FHA_2 | 235 | 241 | PF00498 | 0.425 |
LIG_FHA_2 | 479 | 485 | PF00498 | 0.555 |
LIG_FHA_2 | 512 | 518 | PF00498 | 0.436 |
LIG_FHA_2 | 92 | 98 | PF00498 | 0.561 |
LIG_LIR_Apic_2 | 14 | 20 | PF02991 | 0.488 |
LIG_LIR_Gen_1 | 172 | 178 | PF02991 | 0.544 |
LIG_LIR_Gen_1 | 234 | 244 | PF02991 | 0.373 |
LIG_LIR_Gen_1 | 276 | 283 | PF02991 | 0.324 |
LIG_LIR_Nem_3 | 172 | 176 | PF02991 | 0.527 |
LIG_LIR_Nem_3 | 234 | 239 | PF02991 | 0.328 |
LIG_LIR_Nem_3 | 276 | 282 | PF02991 | 0.320 |
LIG_LIR_Nem_3 | 286 | 292 | PF02991 | 0.361 |
LIG_LIR_Nem_3 | 394 | 398 | PF02991 | 0.462 |
LIG_Rb_LxCxE_1 | 151 | 172 | PF01857 | 0.571 |
LIG_SH2_CRK | 17 | 21 | PF00017 | 0.561 |
LIG_SH2_CRK | 289 | 293 | PF00017 | 0.434 |
LIG_SH2_CRK | 83 | 87 | PF00017 | 0.561 |
LIG_SH2_NCK_1 | 236 | 240 | PF00017 | 0.494 |
LIG_SH2_SRC | 9 | 12 | PF00017 | 0.525 |
LIG_SH2_STAT3 | 163 | 166 | PF00017 | 0.516 |
LIG_SH2_STAT5 | 130 | 133 | PF00017 | 0.545 |
LIG_SH2_STAT5 | 159 | 162 | PF00017 | 0.561 |
LIG_SH2_STAT5 | 163 | 166 | PF00017 | 0.561 |
LIG_SH2_STAT5 | 236 | 239 | PF00017 | 0.397 |
LIG_SH2_STAT5 | 312 | 315 | PF00017 | 0.481 |
LIG_SH2_STAT5 | 387 | 390 | PF00017 | 0.433 |
LIG_SH2_STAT5 | 9 | 12 | PF00017 | 0.488 |
LIG_SH3_2 | 106 | 111 | PF14604 | 0.404 |
LIG_SH3_3 | 101 | 107 | PF00018 | 0.535 |
LIG_SH3_3 | 226 | 232 | PF00018 | 0.522 |
LIG_SH3_3 | 257 | 263 | PF00018 | 0.598 |
LIG_SH3_3 | 442 | 448 | PF00018 | 0.664 |
LIG_SH3_3 | 449 | 455 | PF00018 | 0.415 |
LIG_SUMO_SIM_anti_2 | 220 | 227 | PF11976 | 0.493 |
LIG_SUMO_SIM_anti_2 | 77 | 84 | PF11976 | 0.497 |
LIG_SUMO_SIM_par_1 | 77 | 84 | PF11976 | 0.513 |
LIG_TRAF2_1 | 155 | 158 | PF00917 | 0.554 |
LIG_TRAF2_1 | 399 | 402 | PF00917 | 0.566 |
LIG_TYR_ITAM | 286 | 306 | PF00017 | 0.517 |
LIG_TYR_ITIM | 81 | 86 | PF00017 | 0.571 |
LIG_WW_2 | 263 | 266 | PF00397 | 0.591 |
LIG_WW_3 | 105 | 109 | PF00397 | 0.571 |
MOD_CK1_1 | 116 | 122 | PF00069 | 0.508 |
MOD_CK1_1 | 234 | 240 | PF00069 | 0.475 |
MOD_CK1_1 | 245 | 251 | PF00069 | 0.502 |
MOD_CK1_1 | 339 | 345 | PF00069 | 0.594 |
MOD_CK1_1 | 383 | 389 | PF00069 | 0.451 |
MOD_CK1_1 | 406 | 412 | PF00069 | 0.516 |
MOD_CK1_1 | 507 | 513 | PF00069 | 0.553 |
MOD_CK2_1 | 245 | 251 | PF00069 | 0.444 |
MOD_CK2_1 | 5 | 11 | PF00069 | 0.564 |
MOD_CK2_1 | 511 | 517 | PF00069 | 0.450 |
MOD_CK2_1 | 569 | 575 | PF00069 | 0.727 |
MOD_CK2_1 | 91 | 97 | PF00069 | 0.561 |
MOD_GlcNHglycan | 118 | 121 | PF01048 | 0.299 |
MOD_GlcNHglycan | 178 | 181 | PF01048 | 0.305 |
MOD_GlcNHglycan | 191 | 194 | PF01048 | 0.135 |
MOD_GlcNHglycan | 283 | 286 | PF01048 | 0.410 |
MOD_GlcNHglycan | 318 | 321 | PF01048 | 0.501 |
MOD_GlcNHglycan | 336 | 339 | PF01048 | 0.626 |
MOD_GlcNHglycan | 424 | 427 | PF01048 | 0.592 |
MOD_GlcNHglycan | 469 | 472 | PF01048 | 0.406 |
MOD_GSK3_1 | 109 | 116 | PF00069 | 0.542 |
MOD_GSK3_1 | 120 | 127 | PF00069 | 0.517 |
MOD_GSK3_1 | 332 | 339 | PF00069 | 0.406 |
MOD_GSK3_1 | 47 | 54 | PF00069 | 0.497 |
MOD_GSK3_1 | 486 | 493 | PF00069 | 0.492 |
MOD_GSK3_1 | 500 | 507 | PF00069 | 0.475 |
MOD_GSK3_1 | 518 | 525 | PF00069 | 0.498 |
MOD_LATS_1 | 415 | 421 | PF00433 | 0.610 |
MOD_N-GLC_1 | 120 | 125 | PF02516 | 0.357 |
MOD_N-GLC_1 | 218 | 223 | PF02516 | 0.277 |
MOD_N-GLC_1 | 558 | 563 | PF02516 | 0.769 |
MOD_NEK2_1 | 176 | 181 | PF00069 | 0.525 |
MOD_NEK2_1 | 242 | 247 | PF00069 | 0.501 |
MOD_NEK2_1 | 334 | 339 | PF00069 | 0.549 |
MOD_NEK2_1 | 488 | 493 | PF00069 | 0.425 |
MOD_NEK2_2 | 120 | 125 | PF00069 | 0.571 |
MOD_NEK2_2 | 380 | 385 | PF00069 | 0.494 |
MOD_PIKK_1 | 206 | 212 | PF00454 | 0.533 |
MOD_PIKK_1 | 254 | 260 | PF00454 | 0.522 |
MOD_PIKK_1 | 339 | 345 | PF00454 | 0.668 |
MOD_PIKK_1 | 371 | 377 | PF00454 | 0.453 |
MOD_PIKK_1 | 508 | 514 | PF00454 | 0.515 |
MOD_PIKK_1 | 91 | 97 | PF00454 | 0.498 |
MOD_PKA_1 | 351 | 357 | PF00069 | 0.612 |
MOD_PKA_1 | 518 | 524 | PF00069 | 0.635 |
MOD_PKA_1 | 98 | 104 | PF00069 | 0.479 |
MOD_PKA_2 | 351 | 357 | PF00069 | 0.590 |
MOD_PKA_2 | 467 | 473 | PF00069 | 0.399 |
MOD_PKA_2 | 477 | 483 | PF00069 | 0.422 |
MOD_PKA_2 | 486 | 492 | PF00069 | 0.495 |
MOD_PKA_2 | 51 | 57 | PF00069 | 0.559 |
MOD_PKA_2 | 518 | 524 | PF00069 | 0.608 |
MOD_PKA_2 | 75 | 81 | PF00069 | 0.531 |
MOD_PKA_2 | 98 | 104 | PF00069 | 0.488 |
MOD_Plk_1 | 242 | 248 | PF00069 | 0.476 |
MOD_Plk_1 | 508 | 514 | PF00069 | 0.479 |
MOD_Plk_4 | 159 | 165 | PF00069 | 0.552 |
MOD_Plk_4 | 212 | 218 | PF00069 | 0.530 |
MOD_Plk_4 | 231 | 237 | PF00069 | 0.230 |
MOD_Plk_4 | 500 | 506 | PF00069 | 0.449 |
MOD_Plk_4 | 75 | 81 | PF00069 | 0.489 |
MOD_ProDKin_1 | 124 | 130 | PF00069 | 0.567 |
MOD_SUMO_rev_2 | 183 | 192 | PF00179 | 0.469 |
TRG_DiLeu_BaEn_1 | 372 | 377 | PF01217 | 0.506 |
TRG_ENDOCYTIC_2 | 235 | 238 | PF00928 | 0.362 |
TRG_ENDOCYTIC_2 | 289 | 292 | PF00928 | 0.386 |
TRG_ENDOCYTIC_2 | 303 | 306 | PF00928 | 0.359 |
TRG_ENDOCYTIC_2 | 395 | 398 | PF00928 | 0.492 |
TRG_ENDOCYTIC_2 | 83 | 86 | PF00928 | 0.561 |
TRG_ER_diArg_1 | 195 | 197 | PF00400 | 0.561 |
TRG_ER_diArg_1 | 300 | 302 | PF00400 | 0.392 |
TRG_ER_diArg_1 | 313 | 315 | PF00400 | 0.385 |
TRG_ER_diArg_1 | 465 | 468 | PF00400 | 0.424 |
TRG_ER_diArg_1 | 518 | 520 | PF00400 | 0.596 |
TRG_ER_diArg_1 | 73 | 76 | PF00400 | 0.566 |
TRG_NLS_MonoExtN_4 | 348 | 355 | PF00514 | 0.600 |
TRG_Pf-PMV_PEXEL_1 | 196 | 201 | PF00026 | 0.355 |
TRG_Pf-PMV_PEXEL_1 | 321 | 326 | PF00026 | 0.420 |
TRG_Pf-PMV_PEXEL_1 | 34 | 39 | PF00026 | 0.361 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1I835 | Leptomonas seymouri | 63% | 99% |
A0A0S4ILZ5 | Bodo saltans | 33% | 100% |
A0A0S4JAK8 | Bodo saltans | 29% | 100% |
A0A1X0P557 | Trypanosomatidae | 39% | 100% |
A0A3R7RG04 | Trypanosoma rangeli | 27% | 70% |
A0A3S7X0L0 | Leishmania donovani | 92% | 100% |
A0A422N1U3 | Trypanosoma rangeli | 41% | 100% |
A4HFL7 | Leishmania braziliensis | 78% | 99% |
A4I352 | Leishmania infantum | 93% | 100% |
D0A5U8 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 38% | 100% |
E9AYZ6 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 89% | 100% |
V5AT41 | Trypanosoma cruzi | 38% | 100% |
V5BDQ7 | Trypanosoma cruzi | 27% | 95% |